net earnings for the quarter were $num-one million or $num-two per diluted share.
given the improved top line growth expectations, we are raising our adjusted earnings per share guidance to $num-one to $num-two, up from prior guidance of $num-three to $num-four.
revenue totaled $num-one billion, adjusted earnings per share reached $num-two, and free cash flow was $num-three million.
revenue for the quarter was $num-one billion, an increase of num-two% over last year due to organic growth of num-three%, acquisitions of num-four% and favorable foreign currency translation of num-five basis points.
this guidance range also includes the expectation that the base business will grow num-one% to num-two%, while covid testing is expected to be down num-three% to down num-four%.
we are raising our expectations for revenue to grow in diagnostics by num-one% to num-two% from prior guidance of minus num-three% to plus num-four%.
this guidance range also includes the expectation that the base business will grow num-one% to num-two%.
we averaged num-one tests per day in september, with volumes declining week-over-week since that time.
we continue to expect our full year adjusted tax rate to be approximately num-one%.
adjusted eps, which exclude amortization, restructuring charges and special items, were $num-one in the quarter, down from $num-two last year.
pcr testing volume averaged num-one per day in the quarter, up from num-two per day in the second quarter.
the base business for both diagnostics and drug development performed well with num-one% and num-two% growth, respectively.
revenue for the quarter was $num-one billion, an increase of num-two% compared to last year due to organic base business growth of num-three%, acquisitions of num-four% and favorable foreign currency translation of num-five basis points.
excluding these items, adjusted operating income in the quarter was $num-one million or num-two% of revenue compared to $num-three billion or num-four% last year.
the num-one% increase in organic revenue is driven by a num-two% increase in the company's organic base business partially offset by a num-three% decrease in covid testing.
operating income for the quarter was $num-one million or num-two% of revenue.